Onco-hematology
How I Treat series on plasma cell dyscrasias.
18 May, 2022 | 10:31h | UTCEditorial: Introduction to a How I Treat series on plasma cell dyscrasias – Blood
How I treat relapsed multiple myeloma – Blood
How I treat frontline transplantation-eligible multiple myeloma – Blood
RCT: Fixed-duration Ibrutinib-Venetoclax in patients with chronic lymphocytic leukemia and comorbidities.
16 May, 2022 | 01:47h | UTC
Commentary on Twitter
In older patients and/or those with comorbidities with untreated #CLL, treatment with ibrutinib-venetoclax was superior to chlorambucil-obinutuzumab, with fewer events and longer PFS after just over 2 yrs of follow-up. Read about the GLOW trial: https://t.co/gYjksIhp96
#LeuSM pic.twitter.com/aBnpdeKhFO— NEJM Evidence (@NEJMEvidence) May 13, 2022
Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukemia, by subtype, during 2000–14: analysis of individual data from 258 cancer registries in 61 countries.
12 May, 2022 | 10:02h | UTC
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.
29 Apr, 2022 | 10:51h | UTC
Commentary on Twitter
??Review Article @ASHE_Journal
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them #IDTwitter #medtwitter #TwitteRx #MedEd https://t.co/ToPLQXtC4r pic.twitter.com/pZQWWb3ZSx— Antibiotic Steward Bassam Ghanem?? (@ABsteward) April 28, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license
Guidelines: Cutaneous lymphomas.
25 Apr, 2022 | 00:38h | UTC
State of the Art Review: Novel treatments in B cell non-Hodgkin’s lymphomas.
22 Apr, 2022 | 09:24h | UTCNovel treatments in B cell non-Hodgkin’s lymphomas – The BMJ
Commentary on Twitter
READ: new State of the Art review on novel treatments in B cell non-Hodgkin’s lymphomas.
Learn about mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in treatment https://t.co/EIri6jDBcv
— The BMJ (@bmj_latest) April 22, 2022
British Guideline for the treatment of chronic lymphocytic leukemia.
21 Apr, 2022 | 10:00h | UTCGuideline for the treatment of chronic lymphocytic leukaemia – British Journal of Haematology
RCT: Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
21 Apr, 2022 | 09:56h | UTCIvosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Ivosidenib and azacitidine showed clinical benefit as compared with placebo and azacitidine in patients with newly diagnosed IDH1-mutated AML, a difficult-to-treat population. https://t.co/6K6mWJdd2V pic.twitter.com/qOwOvHcV4j
— NEJM (@NEJM) April 20, 2022
Pre-transplant EASIX (endothelial activation and stress index) may predict the hazard of sepsis after allogeneic stem cell transplantation.
19 Apr, 2022 | 02:04h | UTCPre-transplant EASIX and sepsis after allogeneic stem cell transplantation – Intensive Care Medicine
Commentary on Twitter
? Endothelial complications major causes of mortality post alloSCT. Pre Tx Endothelial Activation & Stress IndeX EASIX (basic lab data characterizing Tx-associated thrombotic microangiopathy) powerful marker of #sepsis, dysfunctional endothelial response.https://t.co/FRGUGT8L78 pic.twitter.com/VF2wTLCHaM
— Intensive Care Medicine (@yourICM) April 18, 2022
Cohort Study: Non-O blood type is associated with increased risk of venous thromboembolism in patients with cancer.
14 Apr, 2022 | 08:29h | UTCABO blood group type and risk of venous thromboembolism in patients with cancer – Blood Advances (link to abstract – $ for full-text)
Review: Cutaneous manifestations of monoclonal gammopathy.
14 Apr, 2022 | 08:21h | UTCCutaneous manifestations of monoclonal gammopathy – Blood Cancer Journal
Review | Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma.
14 Apr, 2022 | 08:03h | UTC
NCCN Guidelines: CAR T-cell–related toxicities in patients with cancer.
11 Apr, 2022 | 01:32h | UTCRelated:
Reviews: CAR T-Cell Therapy Toxicities and Side Effects
Reviews: CAR T-Cell Therapy Toxicities and Side Effects
Critical Care Management of Chimeric Antigen Receptor T Cell–related Toxicity. Be Aware and Prepared
Reviews: CAR T-Cell Therapy Toxicities and Side Effects
Before-and-after study: Antimicrobial stewardship in high-risk febrile neutropenia patients reduced carbapenem and glycopeptide use and was associated with improved clinical outcomes.
4 Apr, 2022 | 00:49h | UTCRelated:
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology
Commentary from the author on Twitter (thread – click for more)
? Our new study "Antimicrobial stewardship in high-risk febrile neutropenia patients." is now out in #ARIC !?
Find our open access paper here: https://t.co/2fFoHfpEzi
And some data bellow ⬇️ (1/10) pic.twitter.com/kg4pYQs9HD
— Adrien Contejean (@AdrienContejean) March 29, 2022
Practice review: Evidence-based and effective management of anemia in palliative care patients.
1 Apr, 2022 | 08:21h | UTC
Practice review: Evidence-based and effective management of fatigue in patients with advanced cancer.
1 Apr, 2022 | 08:26h | UTC
Review: The use of virtual care in patients with hematologic malignancies.
1 Apr, 2022 | 08:18h | UTC
Guidance on the need for contraception related to use of pharmaceuticals: providing information on the proper use of pharmaceuticals in patients with reproductive potential.
31 Mar, 2022 | 07:49h | UTC
Review | Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
28 Mar, 2022 | 08:47h | UTCPreparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
In a new Review now online, @abouelem and co-authors discuss the preparation and management of patients with cancer before #CARTcells, an area in which evidence on optimal conditions needs to grow https://t.co/Sb6rgcOTTJ pic.twitter.com/wjRrPDpoT7
— NatureRevClinOncol (@NatRevClinOncol) March 23, 2022
Cohort study: Long-term treatment with clozapine is associated with increased risk of hematological malignancies.
28 Mar, 2022 | 08:43h | UTCLong-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
Clozapine associated with an increased risk of haematological malignancies with a dose-response effect.
More deaths than from agranulocytosis, but absolute risk small compared to overall mortality benefit with clozapine.https://t.co/BK3P7GgPiv@TheLancetPsych
— Jonathan Rogers (@drjprogers) March 24, 2022
First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022.
28 Mar, 2022 | 08:46h | UTC
Phase 2 RCT: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia.
21 Mar, 2022 | 08:22h | UTCVenetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW: Results from the HOVON 139/GiVe, ph 2 trial show that consolidation with venetoclax after fixed-duration venetoclax + obinutuzumab in patients w/ previously untreated CLL increases known side-effects & does not prevent MRD and risk of relapse #lymsm https://t.co/VzCUSHPMrp pic.twitter.com/PB62XNLAIK
— The Lancet Haematology (@TheLancetHaem) March 2, 2022
RCT: Efficacy of Plinabulin vs. Pegfilgrastim for prevention of docetaxel-induced neutropenia in patients with solid tumors.
18 Mar, 2022 | 08:00h | UTC
Commentary on Twitter
This RCT found that same-day plinabulin, a novel selective immunomodulating microtubule binding agent (SIMBA), is noninferior to next-day pegfilgrastim in chemotherapy-induced neutropenia prevention in patients receiving docetaxel chemotherapy. https://t.co/tUXuffISmB pic.twitter.com/LROsd3trPv
— JAMA Network Open (@JAMANetworkOpen) January 27, 2022
RCT: Bortezomib in newly diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
18 Mar, 2022 | 07:50h | UTCChildren’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
17 Mar, 2022 | 08:45h | UTC